Tirzepatide
Metabolic / Dual Incretin Agonist
Approved (T2D 2022, obesity 2023)
GLP-1 AgonistGIP AgonistFDA ApprovedWeight ManagementMetabolic
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. By simultaneously activating both incretin receptors, t…
Full Tirzepatide profile →
Liraglutide
Metabolic / GLP-1 Agonist
Approved (T2D, obesity, pediatric obesity)
GLP-1 AgonistFDA ApprovedWeight ManagementMetabolicDiabetes
Liraglutide is a once-daily GLP-1 receptor agonist developed by Novo Nordisk that was the first GLP-1 agent approved for weight management (Saxenda, 2014) and established the proof-of-concept for GLP-1-based obesity phar…
Full Liraglutide profile →
Stack Compatibility & Key Differences
Both are active research compounds. See individual pages for full protocol data.
Frequently Asked Questions
What is the difference between Tirzepatide and Liraglutide?
Tirzepatide: Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. By simultaneously activating both incretin receptors, t… Liraglutide: Liraglutide is a once-daily GLP-1 receptor agonist developed by Novo Nordisk that was the first GLP-1 agent approved for weight management (Saxenda, 2014) and established the proof-of-concept for GLP-1-based obesity phar…
Can you stack Tirzepatide and Liraglutide?
Both are active research compounds. See individual pages for full protocol data.
Which has a longer half-life, Tirzepatide or Liraglutide?
Tirzepatide half-life: ~120 hours (5 days). Liraglutide half-life: ~13 hours.